Coronavirus disease 2019 (COVID-19) induced by SARS-Cov-2 can be related to coagulopathy . Also, the infection-induced inflammatory changes are found in patients with disseminated intravascular coagulopathy (DIC). The lack of previous immunity to COVID-19 has caused infection of a large number of patients worldwide and unpredictability regarding the management of the complications that appear in the course of this viral illness . Lungs are the most important target organ of the SARS-COV-2 . In COVID-19 patients, acute lung injury leads to respiratory failure . However, multiorgan failure can also occur in these patients . The primary coagulopathy of COVID-19 is marked by a considerable elevation of D-dimer, ferritin, and fibrinogen degradation products . In comparison, abnormalities in platelet count, prothrombin time, and partial thromboplastin time are partly uncommon in initial presentations . Inflammatory biomarkers including CRP, LDH, and IL-6 are significantly elevated in the early stages of the disease . In this regard, inflammation-associated biomarkers and coagulation test screening, including the assessment of IL-6, CRP, LDH, D-dimer, platelet count, PT & PTT time, ferritin, and fibrinogen levels are suggested for detecting infection by this virus . Overall, COVID-19-associated coagulopathy should be managed like other patients with critical conditions, and supportive care and thromboembolic prophylaxis should be used for severe patients.